Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Common Equity (2016 - 2025)

Historic Common Equity for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $122.3 million.

  • OptimizeRx's Common Equity rose 681.26% to $122.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.3 million, marking a year-over-year increase of 681.26%. This contributed to the annual value of $117.0 million for FY2024, which is 755.02% down from last year.
  • Per OptimizeRx's latest filing, its Common Equity stood at $122.3 million for Q3 2025, which was up 681.26% from $119.3 million recorded in Q2 2025.
  • OptimizeRx's 5-year Common Equity high stood at $140.8 million for Q2 2022, and its period low was $114.5 million during Q3 2024.
  • For the 5-year period, OptimizeRx's Common Equity averaged around $123.6 million, with its median value being $122.5 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first surged by 18658.96% in 2021, then tumbled by 1775.51% in 2023.
  • Quarter analysis of 5 years shows OptimizeRx's Common Equity stood at $131.4 million in 2021, then fell by 4.01% to $126.1 million in 2022, then increased by 0.35% to $126.6 million in 2023, then fell by 7.55% to $117.0 million in 2024, then grew by 4.5% to $122.3 million in 2025.
  • Its last three reported values are $122.3 million in Q3 2025, $119.3 million for Q2 2025, and $116.3 million during Q1 2025.